Propylthiouracil (PTU): Uses, Doses, Side Effects, and How It Compares to Other Thyroid Drugs

What Is Propylthiouracil and How Does It Work?

PTU is a thioamide that inhibits thyroid peroxidase, the enzyme that oxidizes iodide and incorporates iodine into thyroglobulin, blocking the synthesis of both T4 and T3. At high doses it also inhibits the deiodinase enzymes that convert T4 to the more biologically active T3 in peripheral tissues. This dual mechanism makes PTU uniquely useful in thyroid storm, where rapid lowering of circulating T3 is a priority.

The FDA approved PTU for hyperthyroidism decades ago, and the drug remains on the FDA drug label as a first-line antithyroid agent only in specific situations: thyroid storm, the first trimester of pregnancy, and patients who cannot tolerate methimazole. Outside those contexts, clinical practice guidelines from the American Thyroid Association (ATA) and the American Association of Clinical Endocrinologists (AACE) favor methimazole because PTU requires three-times-daily dosing and carries substantially greater hepatotoxicity risk [1][2].

Thyroid peroxidase inhibition begins within hours of the first dose. However, PTU does not immediately lower serum T4 or T3 because preformed hormone stored in the thyroid gland continues to be released. Patients typically become biochemically euthyroid within four to eight weeks of starting treatment, though TSH normalization lags by several additional weeks because the pituitary requires time to respond to falling hormone levels [3].

Who Should Take PTU? Indications and Patient Selection

PTU is appropriate for a defined subset of hyperthyroid patients. Methimazole is the default antithyroid drug for most adults and children outside pregnancy, so the correct question is not "which antithyroid drug is better" but "does this patient have a specific indication for PTU?"

First-trimester pregnancy. Methimazole is associated with a specific embryopathy (choanal atresia, aplasia cutis, esophageal/choanal atresia) when used during organogenesis. PTU carries lower teratogenic risk during weeks 6, 10 of gestation, making it the preferred agent in the first trimester. The ATA 2016 guidelines recommend switching to methimazole after the first trimester because the hepatotoxicity risk of PTU outweighs its teratogenic advantage once organogenesis is complete [1].

Thyroid storm. Large doses of PTU (500, 1 to 000 mg loading dose, then 250 mg every four hours) suppress both new hormone synthesis and peripheral T4-to-T3 conversion within hours. The 2016 ATA thyroid storm protocol places PTU alongside beta-blockers, iodine solution, and corticosteroids as a front-line intervention [1].

Methimazole allergy or intolerance. Patients with agranulocytosis or severe rash on methimazole may be candidates for PTU, though cross-reactivity between the two drugs is possible in roughly 50% of allergic cases [4].

Patients preparing for radioactive iodine (RAI) who need rapid pre-treatment control. PTU is sometimes chosen because it may blunt the hypothyroidism that follows RAI less than methimazole, though the evidence on this point is not conclusive.

Dosing: How Much PTU Do Patients Actually Need?

Standard adult dosing for mild-to-moderate Graves hyperthyroidism runs 100 to 150 mg three times daily (300 to 450 mg/day total). Severe hyperthyroidism or thyroid storm requires doses up to 1 to 200 mg/day. Once the patient reaches a euthyroid state, the dose is tapered. Maintenance usually falls between 50 mg two to three times daily.

Pediatric dosing is weight-based. Children typically receive 5 to 7 mg/kg/day divided into three doses, with a ceiling of 300 mg/day for most children. The ATA and AACE do not recommend PTU as a first-line drug for pediatric Graves disease given the hepatotoxicity risk; methimazole is preferred [2][5].

Pregnancy dosing targets the minimum amount needed to keep free T4 in the upper third of the normal reference range, because PTU crosses the placenta and can cause fetal hypothyroidism or goiter. Most pregnant women with Graves disease achieve control on 100 to 300 mg/day total in divided doses [1].

The Black-Box Warning: Hepatotoxicity You Cannot Ignore

The FDA added a black-box warning to PTU in 2010 after reviewing 32 cases of serious liver injury in adults and 12 in children, including 13 deaths and 11 liver transplants [6]. This risk is not trivial.

The hepatotoxicity from PTU appears to be immunologically mediated rather than dose-dependent, meaning no safe lower dose threshold has been established. Onset typically occurs within the first six months of treatment but can appear at any time. Patients should be told to stop PTU immediately and seek evaluation if they develop jaundice, dark urine, abdominal pain, unusual fatigue, or nausea that is not explained by their hyperthyroidism.

Monitoring recommendations: baseline liver function tests (LFTs) and a complete blood count (CBC) before starting PTU, repeated every four to six weeks during the first six months, then every three months thereafter. Any elevation of transaminases above three times the upper limit of normal warrants discontinuation [6][7].

Agranulocytosis, though more commonly associated with methimazole in some series, also occurs with PTU. Patients must be instructed to report fever or sore throat immediately. A CBC with differential should be obtained urgently, and PTU should be stopped if the absolute neutrophil count drops below 1,000 cells/mm³ [2].

PTU vs. Methimazole: A Direct Comparison

Methimazole and PTU both block thyroid peroxidase, but they differ in pharmacokinetics, dosing schedule, and risk profile. The table below summarizes the key distinctions.

| Feature | PTU | Methimazole | |---|---|---| | Dosing frequency | 3 times daily | Once daily | | Potency ratio | 1 mg | ~10 to 15 mg equivalent effect | | Peripheral T4-to-T3 block | Yes | No | | First-trimester safety | Preferred | Avoided | | Hepatotoxicity risk | Black-box warning | Lower (cholestasis, rare) | | Agranulocytosis risk | Similar (<0.5%) | Similar (<0.5%) | | Typical initial dose | 300 to 450 mg/day | 20 to 40 mg/day | | Remission rate at 12 to 18 months | ~40 to 50% | ~40 to 50% |

The remission rates at 12 to 18 months are broadly similar between the two drugs. A 2019 Cochrane review of antithyroid drug therapy found no statistically significant difference in remission rates when comparing thioamides head-to-head, although direct PTU-versus-methimazole randomized data are limited [8]. The practical advantages of methimazole (once-daily dosing, better tolerability, lower liver risk) explain why it is the default choice in current guidelines.

Thyroid Storm: PTU as a Life-Saving Drug

Thyroid storm carries a mortality rate of 10 to 30% even with aggressive treatment [9]. PTU at a loading dose of 500, 1 to 000 mg given via nasogastric tube (since there is no intravenous formulation) is standard care because it blocks both synthesis and peripheral conversion within 60 to 90 minutes. Methimazole does not block peripheral conversion and is therefore inferior in this acute setting.

The Burch-Wartofsky Point Scale (BWPS), validated for clinical use, scores hyperthermia, tachycardia, CNS effects, heart failure, and precipitating factors. A score of 45 or above indicates thyroid storm and should trigger immediate PTU loading alongside propranolol 60 to 80 mg every four hours, hydrocortisone 300 mg IV loading then 100 mg every eight hours, and saturated solution of potassium iodide (SSKI) given one hour after the first PTU dose [1][9].

Radioactive Iodine vs. PTU vs. Surgery: Choosing a Definitive Therapy

For patients with Graves disease who are not pregnant and have no contraindications, the three definitive options are RAI, thyroidectomy, and long-term antithyroid drug therapy. Each approach has specific advantages.

RAI (iodine-131) destroys thyroid tissue and produces permanent hypothyroidism requiring lifelong levothyroxine in most patients. A single dose achieves euthyroidism or hypothyroidism in 80 to 90% of patients within six months [10]. RAI is contraindicated in pregnancy, in active moderate-to-severe Graves orbitopathy, and when very rapid control is needed.

Thyroidectomy offers the fastest and most predictable control of hyperthyroidism. In high-volume centers the complication rate for permanent hypoparathyroidism is below 2% and for permanent recurrent laryngeal nerve injury below 1% [11]. PTU is used for four to eight weeks preoperatively to render the patient euthyroid before surgery.

Long-term antithyroid drug therapy with methimazole (or PTU in appropriate patients) for 12 to 18 months produces remission in roughly 40 to 50% of Graves disease patients. Remission is more likely in patients with small goiters, low TRAb titers at diagnosis, and mild biochemical hyperthyroidism [1].

Levothyroxine (Synthroid, Tirosint): The First-Line Hypothyroidism Treatment

PTU treats hyperthyroidism. The opposite condition, hypothyroidism, is treated with thyroid hormone replacement. Levothyroxine (T4) is the standard of care for hypothyroidism based on its consistent bioavailability, long half-life (approximately seven days), and extensive safety data across decades of use.

The AACE and ATA both recommend levothyroxine as the preferred therapy for hypothyroidism [12]. The average replacement dose in adults is 1.6 mcg/kg/day, although individual titration based on TSH is required. Elderly patients and those with cardiovascular disease typically start at 12.5 to 25 mcg/day with slow uptitration.

Tirosint is a liquid gel-cap formulation of levothyroxine that eliminates common absorption issues caused by fillers. A 2021 study published in Thyroid found that patients with documented malabsorption syndromes achieved significantly better TSH control on liquid levothyroxine than on tablet formulations [13]. Tirosint-SOL, the liquid solution version, is particularly useful for patients with dysphagia or those taking their medication via feeding tube.

Drug and food interactions significantly affect levothyroxine absorption. Calcium carbonate, ferrous sulfate, proton pump inhibitors, and high-fiber meals all reduce absorption when taken within four hours of the levothyroxine dose. Patients should take levothyroxine on an empty stomach, 30 to 60 minutes before food or coffee, for consistent absorption [12].

Liothyronine (Cytomel): When T3 Therapy Is Added

Liothyronine is synthetic T3, the biologically active thyroid hormone. Most patients convert T4 to T3 efficiently via deiodinase enzymes in peripheral tissues, making T3 supplementation unnecessary. However, a subset of patients, particularly those with the DIO2 Thr92Ala polymorphism, may have impaired T4-to-T3 conversion and report persistent symptoms on levothyroxine monotherapy despite normal TSH [14].

Adding low-dose liothyronine (typically 5 to 25 mcg/day in one or two divided doses) to levothyroxine can improve mood, cognition, and energy in selected patients. The 2019 ATA task force on combination T4/T3 therapy concluded that the evidence does not support routine combination therapy but acknowledged that a trial may be reasonable in patients who remain symptomatic on optimized levothyroxine with normal TSH [15].

Liothyronine has a short half-life of approximately one day. This produces peaks and troughs in serum T3 that can cause palpitations or anxiety, especially at doses above 25 mcg/day. Sustained-release compounded liothyronine formulations are used by some clinicians to smooth this profile, though the FDA has not approved any sustained-release T3 product.

Armour Thyroid and Natural Desiccated Thyroid (NDT)

Natural desiccated thyroid (NDT), sold as Armour Thyroid, NP Thyroid, and WP Thyroid, is derived from dried porcine thyroid gland. It contains both T4 and T3 in a fixed ratio of approximately 4:1 (by weight), which is biologically higher in T3 relative to human thyroid secretion (which produces a T4:T3 ratio closer to 14:1 by weight) [16].

Some patients who feel unwell on levothyroxine report improved well-being on NDT. A 2013 randomized crossover trial by Hoang et al. (N=70) published in the Journal of Clinical Endocrinology and Metabolism found that 49% of participants preferred NDT over levothyroxine, with NDT associated with modest weight loss and improved mood scores [17]. The ATA and AACE do not recommend NDT as first-line therapy for hypothyroidism, citing the lack of large long-term outcome data and the variable T3 content of animal-derived preparations [12].

Armour Thyroid is dosed in grains. One grain (60 mg) contains approximately 38 mcg T4 and 9 mcg T3. Patients switching from levothyroxine to NDT typically receive a dose calculated so that the T4 component matches their previous levothyroxine dose, then titrate based on symptoms and labs. TSH alone is not a reliable monitoring marker on NDT because the higher T3 content suppresses TSH at doses that may be physiologically appropriate; free T3 and free T4 measurements provide a more complete picture [16].

HealthRX Clinical Decision Framework: Matching the Drug to the Clinical Context

The following decision tree summarizes which thyroid drug is appropriate for which scenario, based on current ATA, AACE, and FDA guidance.

1. Hyperthyroidism, not pregnant, not in thyroid storm: Start methimazole. Use PTU only if methimazole is contraindicated or not tolerated.
2. Hyperthyroidism, first trimester of pregnancy: Use PTU. Switch to methimazole or consider thyroidectomy in the second trimester.
3. Thyroid storm: PTU 500, 1 to 000 mg loading dose plus propranolol, iodine, and corticosteroids. This is a medical emergency.
4. Hypothyroidism, standard presentation: Levothyroxine at 1.6 mcg/kg/day, titrated to TSH 0.5, 2.5 mIU/L.
5. Hypothyroidism with malabsorption or inconsistent tablet absorption: Consider Tirosint or Tirosint-SOL liquid gel-cap levothyroxine.
6. Persistent hypothyroid symptoms on optimized levothyroxine with normal TSH: Consider a supervised trial of low-dose liothyronine 5 to 12.5 mcg/day added to a reduced levothyroxine dose.
7. Patient preference for NDT: Armour Thyroid is a reasonable option if the patient is informed of the higher T3 content, the need for free T3/T4 monitoring, and the absence of long-term outcome trials.

Monitoring PTU Therapy: Lab Schedule and What to Watch For

Monitoring PTU is more intensive than monitoring methimazole because of the hepatotoxicity risk.

Before starting: Baseline TSH, free T4, free T3, LFTs (AST, ALT, alkaline phosphatase, total bilirubin), CBC with differential, and TRAb if Graves disease is suspected.

Weeks 4, 8: Repeat free T4 and free T3. TSH often remains suppressed even when free thyroid hormones have normalized because pituitary recovery lags. Do not use TSH alone to guide early dose adjustments [3]. Repeat LFTs and CBC.

Months 2, 6: Monthly LFTs and CBC. TSH, free T4, and free T3 every four to six weeks until stable. Any jaundice, abdominal pain, or dark urine requires immediate discontinuation and hepatology consultation.

After six months of stable therapy: LFTs and CBC every three months. TSH, free T4 every three months.

At 12 to 18 months: Consider TRAb measurement to assess likelihood of remission before attempting drug discontinuation. A negative TRAb suggests a higher probability of sustained remission [1].

Drug Interactions, Contraindications, and Special Populations

PTU is highly protein-bound (approximately 80% albumin-bound) and is metabolized by hepatic glucuronidation. Several clinically relevant interactions exist.

Warfarin: PTU can potentiate warfarin by both decreasing vitamin K-dependent clotting factor synthesis (as hyperthyroidism itself accelerates clotting factor catabolism, which corrects as euthyroidism is restored) and by a direct drug interaction. INR must be monitored closely when starting or stopping PTU in anticoagulated patients [7].

Digoxin: Hyperthyroidism increases digoxin clearance. As PTU restores euthyroidism, digoxin levels may rise and require dose adjustment.

Beta-blockers: Propranolol clearance also decreases as thyroid hormone levels fall. Doses may need reduction once euthyroidism is achieved.

Contraindications: Known hypersensitivity to PTU or any component. Severe hepatic impairment. Prior PTU-induced agranulocytosis or severe hepatotoxicity (do not rechallenge).

Breastfeeding: PTU transfers into breast milk at low levels, approximately 0.025% of the maternal dose. At doses below 300 mg/day, PTU is considered compatible with breastfeeding by the ATA, with infant thyroid function monitored at four to six weeks [1].

Pediatric patients: PTU is not recommended as first-line antithyroid therapy in children. Cases of severe and fatal hepatotoxicity in pediatric patients prompted the FDA to issue a safety communication specifically warning against pediatric PTU use except when other therapies are not possible [6].

What Happens After PTU: Remission, Relapse, and Long-Term Outcomes

Approximately 40 to 50% of Graves disease patients treated with antithyroid drugs for 12 to 18 months achieve remission, defined as a normal TSH and free T4 six months after drug discontinuation [1]. Relapse is more likely in patients with large goiters, persistently elevated TRAb titers at the end of therapy, severe hyperthyroidism at diagnosis, and cigarette smoking.

Patients who relapse after one course of antithyroid drug therapy may receive a second course, though the remission rate for repeat courses is lower. The ATA recommends considering definitive therapy (RAI or thyroidectomy) for patients who relapse, rather than indefinite antithyroid drug use [1].

Patients who undergo RAI or thyroidectomy require lifelong monitoring. After RAI, hypothyroidism develops in 80% or more of patients within six months [10]. Thyroidectomy produces immediate hypothyroidism requiring lifelong levothyroxine. Levothyroxine replacement should be started within 24 hours of total thyroidectomy to prevent postoperative hypothyroid symptoms.